The announcement comes months after UniQure became embroiled in a public debate with FDA leaders over the clinical trial data supporting its application.

The health insurer Centene did not indicate to how many employees were offered buyouts or how much it is aiming to reduce its workforce.

Drugmakers are betting they can crack into the obesity drug market that Novo Nordisk and Eli Lilly currently dominate.

The U.S. will lean on the same playbook it did starting in the late 1950s, part of which involves releasing sterile insects to suppress the pest’s population.

Novo Nordisk and Eli Lilly bring their longtime rivalry to GLP-1 pills and prepare to make their pitch to seniors with Medicare.

Officials are more concerned about highly contagious diseases like measles and respiratory viruses, which can spread quickly through large, fast-moving crowds.

Eli Lilly’s new top dealmaker explains how the company changed its approach to M&A now that it’s the most valuable pharmaceutical company in the world.

An experimental lung cancer drug from Akeso and Summit Therapeutics reduced the risk of death by 34% in a late-stage trial, according to data released Sunday.

President Donald Trump is trying to fast-track research into psychedelics as treatments, creating new opportunities and risks.

Replimune was among the drugmakers that had criticized the FDA for what they called inconsistent guidance around trials and approvals.